Kathryn Spencer
Psychiatric/Mental Health · Lakewood, NJNPI 1457070625
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 87.6% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $8,542, more than ten times the $40 reported in 2022. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $91.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$16K
- Johnson & Johnson$611
- Alkermes, Inc.$503
- Neurocrine Biosciences, Inc.$494
- E.r. Squibb & Sons, L.L.C.$197
- AbbVie$134
- plus $302 from 5 others
What the payments were for
- Speaking & faculty fees$10,45258%
- Travel & lodging$3,49019%
- Food & beverage$3,93222%
- Education$1491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 76 | $15,783 |
| Johnson & Johnson | 27 | $611 |
| Alkermes, Inc. | 28 | $503 |
| Neurocrine Biosciences, Inc. | 25 | $494 |
| E.r. Squibb & Sons, L.L.C. | 12 | $197 |
| AbbVie | 9 | $134 |
| Otsuka America Pharmaceutical, Inc. | 9 | $130 |
| Indivior Inc. | 4 | $64 |
| Tempus AI, Inc | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 3 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$14,804
- INVEGA SUSTENNA$124
How this compares
$18,024 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 90 | $260,482 |
| IngrezzaValbenazine Tosylate | 21 | $174,400 |
| Abilify MaintenaAripiprazole | 43 | $135,847 |
| FanaptIloperidone | 26 | $81,486 |
| LybalviOlanzapine/Samidorphan Malate | 46 | $69,582 |
| VraylarCariprazine Hcl | 27 | $41,901 |
| Paliperidone ErPaliperidone | 79 | $30,185 |
| Clozapine | 263 | $26,210 |
| Lurasidone Hcl | 26 | $8,965 |
| Aripiprazole | 138 | $8,855 |
| Divalproex Sodium ErDivalproex Sodium | 117 | $7,430 |
| Fluphenazine Hcl | 48 | $6,611 |
| Oxcarbazepine | 57 | $3,202 |
| Fluvoxamine Maleate | 72 | $2,632 |
| Divalproex Sodium | 72 | $2,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $611 | $260,48290 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $494 | $174,40021 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $130 | $135,84743 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $47 | $81,48626 claims |
| Alkermes, Inc.Lybalvi | $503 | $69,58246 claims |
| AbbVieVraylar | $134 | $41,90127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Lakewood
- Lauren AravichLakewood$11K
- Telatha SurujnathLakewood$6K
- Ubong UdofiaMarlton$407K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Aaron SpectorMarlton$100K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.